Ascentage Pharma Group International (AAPG) Current Deferred Revenue (2023 - 2025)
Ascentage Pharma Group International (AAPG) has disclosed Current Deferred Revenue for 3 consecutive years, with $5.3 million as the latest value for Q4 2025.
- For Q4 2025, Current Deferred Revenue rose 1.28% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $5.3 million, up 1.28%, while the annual FY2025 figure was $5.4 million, 4.38% up from the prior year.
- Current Deferred Revenue hit $5.3 million in Q4 2025 for Ascentage Pharma Group International, up from $5.2 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $5.3 million in Q4 2023 and bottomed at $5.2 million in Q4 2024.
- Average Current Deferred Revenue over 3 years is $5.3 million, with a median of $5.3 million recorded in 2025.
- Year-over-year, Current Deferred Revenue decreased 2.18% in 2024 and then grew 1.28% in 2025.
- Ascentage Pharma Group International's Current Deferred Revenue stood at $5.3 million in 2023, then fell by 2.18% to $5.2 million in 2024, then increased by 1.28% to $5.3 million in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods came in at $5.3 million, $5.2 million, and $5.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.